Stockreport

EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's [Yahoo! Finance]

Alzamend Neuro, Inc.  (ALZN) 
PDF data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary results were released in June 2023 Identified by an [Read more]